Type 1 Diabetes Pipeline Insight

DelveInsight’s, “Type 1 Diabetes Pipeline Insight, 2026” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Type 1 Diabetes Understanding

Type 1 Diabetes Overview

Type 1 diabetes is a chronic autoimmune disease in which the body’s immune system mistakenly attacks and destroys the insulin-producing beta cells of the pancreas. As a result, the body produces little or no insulin, a hormone required to allow glucose to enter cells for energy production. The disease commonly develops in children, adolescents, and young adults, although it can occur at any age. Symptoms often appear suddenly and may include excessive thirst, frequent urination, weight loss, fatigue, and blurred vision. Without insulin therapy, type 1 diabetes can lead to life-threatening complications such as diabetic ketoacidosis.

The exact cause of type 1 diabetes is not fully understood, but it is believed to result from a combination of genetic susceptibility and environmental triggers. Certain genes related to the human leukocyte antigen (HLA) system increase the risk of developing the disease. Environmental factors such as viral infections, early dietary exposures, and other immune-related triggers may initiate the autoimmune process in genetically predisposed individuals. In type 1 diabetes, the immune system incorrectly identifies pancreatic beta cells as foreign and gradually destroys them, eventually leading to insulin deficiency. Unlike type 2 diabetes, type 1 diabetes is not caused by lifestyle factors such as obesity or lack of physical activity.

The pathophysiology of type 1 diabetes involves autoimmune-mediated destruction of pancreatic beta cells located in the islets of Langerhans. T lymphocytes infiltrate the pancreatic tissue and progressively damage beta cells through inflammatory and immune-mediated mechanisms. Autoantibodies against insulin, glutamic acid decarboxylase (GAD), and other pancreatic antigens are commonly present and serve as markers of autoimmune activity. As beta-cell mass declines, insulin production becomes insufficient to regulate blood glucose levels, resulting in hyperglycemia. Persistent hyperglycemia leads to metabolic disturbances involving carbohydrate, fat, and protein metabolism, and over time may cause microvascular and macrovascular complications affecting the eyes, kidneys, nerves, heart, and blood vessels.

Diagnosis of type 1 diabetes is based on clinical symptoms and laboratory evidence of elevated blood glucose levels. Common diagnostic tests include fasting plasma glucose, random plasma glucose, oral glucose tolerance testing, and glycated hemoglobin (HbA1c) measurement. Individuals with type 1 diabetes often have positive pancreatic autoantibodies, including GAD65, IA-2, insulin autoantibodies, or zinc transporter 8 antibodies, which help distinguish the disease from other forms of diabetes. Measurement of C-peptide levels may also be useful to assess endogenous insulin production. Early diagnosis is important to prevent acute complications such as diabetic ketoacidosis and to begin lifelong insulin replacement therapy.

Treatment of type 1 diabetes primarily involves lifelong insulin replacement therapy because the pancreas can no longer produce adequate insulin. Insulin may be administered through multiple daily injections or continuous subcutaneous insulin infusion using an insulin pump. Careful blood glucose monitoring, carbohydrate counting, regular physical activity, and individualized nutritional planning are essential components of disease management. Continuous glucose monitoring systems and automated insulin delivery technologies have significantly improved glycemic control and reduced the risk of hypoglycemia. In addition to glucose management, patients require regular screening for complications involving the eyes, kidneys, nerves, and cardiovascular system. Education and ongoing medical support are critical for maintaining long-term health and quality of life in individuals with type 1 diabetes.

"Type 1 Diabetes Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 1 Diabetes pipeline landscape is provided which includes the disease overview and Type 1 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 1 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Type 1 Diabetes Pipeline Report Highlights

The Type 1 Diabetes companies and academics are working to assess challenges and seek opportunities that could influence Type 1 Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Type 1 Diabetes.

Type 1 Diabetes Emerging Drugs Analysis

This segment of the Type 1 Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type 1 Diabetes Emerging Drugs

Baricitinib: Lilly

Baricitinib is an oral Janus kinase (JAK) inhibitor developed by Eli Lilly and Company in collaboration with Incyte. Baricitinib works by selectively inhibiting JAK1 and JAK2 signaling pathways involved in autoimmune inflammation, thereby reducing immune-mediated destruction of pancreatic beta cells and helping preserve endogenous insulin production. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Type 1 Diabetes.

Cadisegliatin: vTv Therapeutics

Cadisegliatin is an investigational oral, liver-selective glucokinase activator being developed for adjunctive treatment of Type 1 Diabetes (T1D). The drug is designed to activate hepatic glucokinase and improve glucose utilization and glycogen storage in the liver without directly stimulating pancreatic insulin secretion, thereby helping reduce hyperglycemia and improving glycemic control while potentially lowering the risk of hypoglycemia and ketoacidosis in patients using insulin therapy. Cadisegliatin received the U.S. FDA Breakthrough Therapy Designation for Type 1 Diabetes. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Type 1 Diabetes.

ZT-01: Zucara Therapeutics Inc.

ZT-01 is an investigational once-daily oral therapy being developed for people with Type 1 Diabetes (T1D), particularly to reduce nocturnal hypoglycemia associated with insulin treatment. The drug is a selective inhibitor of the somatostatin receptor type 2 (SSTR2), designed to restore the body’s natural glucagon response during hypoglycemia, by blocking SSTR2 signaling. ZT-01 enhances glucagon secretion from pancreatic alpha cells, thereby helping prevent dangerous low blood glucose episodes without interfering with insulin therapy. ZT-01 has received FDA Fast Track Designation for the prevention of severe hypoglycemia in Type 1 Diabetes. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Type 1 Diabetes.

IMC-S118AI: Immunocore Ltd

IMC-S118AI is an investigational autoimmune therapy being developed for Type 1 Diabetes (T1D) as part of the company’s ImmTAAI (Immune mobilising monoclonal TCRs Against AutoImmune disease) platform. IMC-S118AI is designed as a disease-modifying therapy that specifically targets pancreatic beta cells by recognizing a peptide from pre-pro-insulin presented by HLA-A02 on beta cells and delivering a PD-1 agonist effector signal to suppress pathogenic autoreactive T cells locally, thereby reducing immune-mediated beta-cell destruction. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Type 1 Diabetes.

Further product details are provided in the report……..

Type 1 Diabetes Drug Therapeutic Assessment

This segment of the report provides insights about the different Type 1 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:

Major Type 1 Diabetes Players in Type 1 Diabetes

There are approx. 85+ key companies which are developing the therapies Type 1 Diabetes. The companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e. Phase III include, Lilly, and others.

Type 1 Diabetes Clinical Trial Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Type 1 Diabetes Drug Route of Administration

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various

ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Type 1 Diabetes Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Type 1 Diabetes Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type 1 Diabetes Clinical Trial Activities

The Type 1 Diabetes pipeline report provides insights into different Type 1 Diabetes clinical trials within phase II, I, preclinical and discovery stage. It also analyses Type 1 Diabetes therapeutic drugs key players involved in developing key drugs.

Type 1 Diabetes Pipeline Development Activities

The Type 1 Diabetes clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Diabetes drugs.

Type 1 Diabetes Pipeline Report Insights

• Type 1 Diabetes Pipeline Analysis
• Type 1 Diabetes Therapeutic Assessment
• Type 1 Diabetes Unmet Needs
• Impact of Type 1 Diabetes Drugs

Type 1 Diabetes Pipeline Report Assessment

• Type 1 Diabetes Pipeline Product Profiles
• Type 1 Diabetes Therapeutic Assessment
• Type 1 Diabetes Pipeline Assessment
• Type 1 Diabetes Inactive drugs assessment
• Type 1 Diabetes Market Unmet Needs

Key Questions Answered In The Type 1 Diabetes Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Type 1 Diabetes drugs?
• How many Type 1 Diabetes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type 1 Diabetes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 1 Diabetes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Type 1 Diabetes and their status?
• What are the key designations that have been granted to the emerging drugs?

Type 1 Diabetes Key Players

• Lilly
• vTv Therapeutics
• Oramed, Ltd.
• Novo Nordisk A/S
• SAb Biotherapeutics, Inc.
• Op-T LLC
• Seraxis
• Creative Medical Technology Holdings Inc
• COUR Pharmaceutical Development Company, Inc.
• Sanofi
• Zucara Therapeutics Inc.
• Otsuka Pharmaceutical Factory, Inc.
• Arrowhead Pharmaceuticals
• Alnylam Pharmaceuticals
• Immunocore Ltd

Type 1 Diabetes Key Products

• Baricitinib
• Cadisegliatin
• ORMD-0801
• Cagrisema
• SAB-142
• OPT101
• Allogeneic pancreatic endocrine cell clusters
• CELZ-201
• CNP-103
• Frexalimab
• ZT-01
• OPF-310
• ARO-ALK7
• ALN-4324
• IMC-S118AI